METABOLIC IMAGING OF CANCER AND ITS RESPONSE TO THERAPY

癌症的代谢成像及其对治疗的反应

• 批准号: 6362543
• 负责人: KENNETH A. KROHN
• 金额: $ 179.27万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-12 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6362543
• 关键词: bioimaging /biomedical imaging; human subject; human therapy evaluation; neoplasm /cancer therapy; positron emission tomography; radiopharmacology

The goal of this program is to develop an improved understanding of metabolic differences between tumors and normal tissue, prior to and after initiation of anti-cancer therapy. The practical objective is to determine how these functional differences lead to useful strategies for differentiating tissues based on biochemical characteristics, and then to learn how this information can be applied for better selection of individualized treatment for a patient. The ultimate goal is to use metabolic imaging information to achieve improved treatment outcome for each patient. Clinical cancer research and tumor biology research are complementary parts of each project. All of the projects investigate ways in which metabolic imaging can contribute to more effective treatment of the patient with cancer, as well as to our understanding of mechanisms by which therapy kills or fails to kill tumors. The projects all use positron emission tomography (PET) to provide quantitative imaging information from the whole body and also data on regional heterogeneity. The team of investigators is strongly interdisciplinary. It draws together experts in oncology, nuclear medicine, radiology, radiobiology, neurology and biochemistry, as well as kinetic modeling, statistics, physics, and radiochemistry. The hypothesis that tumor metabolism is a sensitive measure of response to therapy is a broad one. We have chosen to focus on selected aspects that appear most likely to be important and useful indicators of tumor status and to study patients on several occasions. Some studies look into the deeper levels of cellular energetics, beyond the phosphorylation of FDG (Project 1). Others measure tumor growth at the level of DNA replication (Project 2). The hormonal status of tumors is being characterized (Project 4), as are factors such as oxygenation that influence tumor biology as well as response to therapy (Project 3). Throughout the projects, metabolic imaging measurements are tested as predictors of important aspects of treatment outcome. In addition to providing insight into the metabolic response of a patient receiving standard surgical, drug or radiation therapy, PET imaging will provide human data on mechanisms of response in new cancer treatment strategies. As a result of these studies, metabolic images of regional tumor metabolism done before, during, and long after therapy are providing insight into tumor biology that is helping to select evaluate, and even modify therapy for the individual patient.

本课程的目标是加深对 肿瘤组织与正常组织代谢前后的差异 启动抗癌治疗。实际的目标是确定 这些功能差异如何导致有用的策略 根据生化特征区分组织，然后 了解如何将此信息应用于更好地选择 针对患者的个体化治疗。最终目标是使用 代谢成像信息，以实现改善的治疗结果 每一位病人。临床癌症研究和肿瘤生物学研究 每个项目的互补部分。所有的项目都在调查 代谢成像可以帮助更有效地治疗 癌症患者，以及我们对机制的理解 哪种疗法能杀死或不能杀死肿瘤。所有的项目都使用正电子。 发射断层扫描(PET)提供定量成像信息 整个机构，以及关于区域异质性的数据。这支队伍 调查人员具有很强的跨学科性质。它汇聚了来自 肿瘤学、核医学、放射学、放射生物学、神经病学和 生物化学，以及动力学建模、统计学、物理学和 放射化学。 认为肿瘤新陈代谢是反应的敏感指标的假设 治疗是一种广泛的治疗。我们选择将重点放在选定的方面 似乎最有可能是肿瘤状态的重要和有用的指标 并在多个场合对患者进行研究。一些研究着眼于 更深层次的细胞能量学，超越FDG的磷酸化 (项目1)。其他人在DNA复制的水平上衡量肿瘤的生长 (项目2)。正在描述肿瘤的荷尔蒙状态(项目 4)，以及影响肿瘤生物学的氧合等因素 以及对治疗的反应(项目3)。在整个项目中， 代谢成像测量被测试为重要的 治疗结果的各个方面。除了提供对 接受标准手术、药物或药物治疗的患者的代谢反应 放射治疗，PET成像将提供人体数据的机制 对新的癌症治疗策略的反应。作为这些研究的结果， 肿瘤局部代谢的代谢图像在术前、术中和术中 在治疗后很长时间内提供了对肿瘤生物学的洞察 帮助选择、评估甚至修改针对个人的治疗方法 有耐心的。